-
Je něco špatně v tomto záznamu ?
Inhibition of Lipid Accumulation in Skeletal Muscle and Liver Cells: A Protective Mechanism of Bilirubin Against Diabetes Mellitus Type 2
CA. Hana, EM. Klebermass, T. Balber, M. Mitterhauser, R. Quint, Y. Hirtl, A. Klimpke, S. Somloi, J. Hutz, E. Sperr, P. Eder, J. Jašprová, P. Valášková, L. Vítek, E. Heiss, KH. Wagner
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
P 29608
Austrian Science Fund FWF - Austria
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2010
Europe PubMed Central
od 2010
Open Access Digital Library
od 2010-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2010
- Publikační typ
- časopisecké články MeSH
Ectopic lipid accumulation in skeletal muscle and liver drives the pathogenesis of diabetes mellitus type 2 (DMT2). Mild hyperbilirubinaemia has been repeatedly suggested to play a role in the prevention of DMT2 and is known for its capacity to shape an improved lipid phenotype in humans and in animals. To date, the effect of bilirubin on lipid accumulation in tissues that are prone to ectopic lipid deposition is unclear. Therefore, we analyzed the effect of bilirubin on lipid accumulation in skeletal muscle and liver cell lines. C2C12 skeletal mouse muscle and HepG2 human liver cells were treated with physiological concentrations of free fatty acids (FFA) (0.5 mM and 1 mM) and unconjugated bilirubin (UCB) (17.1 and 55 µM). The intracellular presence of UCB upon exogenous UCB administration was confirmed by HPLC and the lipid accumulation was assessed by using Nile red. Exposure of both cell lines to UCB significantly reduced lipid accumulation by up to 23% (p ≤ 0.001) in HepG2 and by up to 17% (p ≤ 0.01) in C2C12 cells at 0.5 and 5 h under hypoglycaemic conditions. Simultaneously, UCB slightly increased FFA uptake in HepG2 cells after 0.5 and 5 h and in C2C12 cells after 12 h as confirmed by gas chromatographic analyses of the remaining FFA content in the incubation media. The effects of UCB on lipid accumulation and uptake were abolished in the presence of higher glucose concentrations. Monitoring the uptake of a radiolabeled glucose analogue [18F]FDG: (2-deoxy-2-[18F]fluoro-D-glucose) into both cell types further indicated higher glucose consumption in the presence of UCB. In conclusion, our findings show that UCB considerably decreases lipid accumulation in skeletal muscle and liver cells within a short incubation time of max. 5 h which suggests that mildly elevated bilirubin levels could lower ectopic lipid deposition, a major key element in the pathogenesis of DMT2.
Department of Nutritional Sciences Faculty of Life Sciences University of Vienna Vienna Austria
Department of Pharmacognosy University of Vienna Vienna Austria
Ludwig Boltzmann Institute Applied Diagnostics Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21010610
- 003
- CZ-PrNML
- 005
- 20210715154733.0
- 007
- ta
- 008
- 210413s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2020.636533 $2 doi
- 035 __
- $a (PubMed)33569010
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Hana, Claudia A $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 245 10
- $a Inhibition of Lipid Accumulation in Skeletal Muscle and Liver Cells: A Protective Mechanism of Bilirubin Against Diabetes Mellitus Type 2 / $c CA. Hana, EM. Klebermass, T. Balber, M. Mitterhauser, R. Quint, Y. Hirtl, A. Klimpke, S. Somloi, J. Hutz, E. Sperr, P. Eder, J. Jašprová, P. Valášková, L. Vítek, E. Heiss, KH. Wagner
- 520 9_
- $a Ectopic lipid accumulation in skeletal muscle and liver drives the pathogenesis of diabetes mellitus type 2 (DMT2). Mild hyperbilirubinaemia has been repeatedly suggested to play a role in the prevention of DMT2 and is known for its capacity to shape an improved lipid phenotype in humans and in animals. To date, the effect of bilirubin on lipid accumulation in tissues that are prone to ectopic lipid deposition is unclear. Therefore, we analyzed the effect of bilirubin on lipid accumulation in skeletal muscle and liver cell lines. C2C12 skeletal mouse muscle and HepG2 human liver cells were treated with physiological concentrations of free fatty acids (FFA) (0.5 mM and 1 mM) and unconjugated bilirubin (UCB) (17.1 and 55 µM). The intracellular presence of UCB upon exogenous UCB administration was confirmed by HPLC and the lipid accumulation was assessed by using Nile red. Exposure of both cell lines to UCB significantly reduced lipid accumulation by up to 23% (p ≤ 0.001) in HepG2 and by up to 17% (p ≤ 0.01) in C2C12 cells at 0.5 and 5 h under hypoglycaemic conditions. Simultaneously, UCB slightly increased FFA uptake in HepG2 cells after 0.5 and 5 h and in C2C12 cells after 12 h as confirmed by gas chromatographic analyses of the remaining FFA content in the incubation media. The effects of UCB on lipid accumulation and uptake were abolished in the presence of higher glucose concentrations. Monitoring the uptake of a radiolabeled glucose analogue [18F]FDG: (2-deoxy-2-[18F]fluoro-D-glucose) into both cell types further indicated higher glucose consumption in the presence of UCB. In conclusion, our findings show that UCB considerably decreases lipid accumulation in skeletal muscle and liver cells within a short incubation time of max. 5 h which suggests that mildly elevated bilirubin levels could lower ectopic lipid deposition, a major key element in the pathogenesis of DMT2.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Klebermass, Eva-Maria $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Balber, Theresa $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria ; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
- 700 1_
- $a Mitterhauser, Markus $u Department of Biomedical Imaging and Image-guided Therapy, Division of Nuclear Medicine, Medical University of Vienna, Vienna, Austria ; Ludwig Boltzmann Institute Applied Diagnostics, Vienna, Austria
- 700 1_
- $a Quint, Ruth $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Hirtl, Yvonne $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Klimpke, Antonia $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Somloi, Sophie $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Hutz, Juliana $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Sperr, Elisabeth $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Eder, Paulina $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 700 1_
- $a Jašprová, Jana $u Institute of Medical Biochemistry and Laboratory Diagnostics, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Valášková, Petra $u Institute of Medical Biochemistry and Laboratory Diagnostics, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Vítek, Libor $u Institute of Medical Biochemistry and Laboratory Diagnostics, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia ; 4 Department of Internal Medicine, University General Hospital and 1 Faculty of Medicine, Charles University, Prague, Czechia
- 700 1_
- $a Heiss, Elke $u Department of Pharmacognosy, University of Vienna, Vienna, Austria
- 700 1_
- $a Wagner, Karl-Heinz $u Department of Nutritional Sciences, Faculty of Life Sciences, University of Vienna, Vienna, Austria
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 11, č. - (2020), s. 636533
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33569010 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210413 $b ABA008
- 991 __
- $a 20210715154733 $b ABA008
- 999 __
- $a ind $b bmc $g 1649879 $s 1130986
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 11 $c - $d 636533 $e 20210125 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- GRA __
- $a P 29608 $p Austrian Science Fund FWF $2 Austria
- LZP __
- $a Pubmed-20210413